Access cutting-edge transthyretin amyloidosis with cardiomyopathy treatment through this clinical trial at a research site in New Brunswick. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this New Brunswick location
Preparing your pre-screening questions…
Access transthyretin amyloidosis with cardiomyopathy specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related transthyretin amyloidosis with cardiomyopathy treatment provided free
Check if you qualify for this transthyretin amyloidosis with cardiomyopathy clinical trial in New Brunswick, NJ
No-Cost Study Care
Local to New Brunswick
Convenient for NJ residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
The purpose of this study is to: * Describe the clinical characteristics of adult patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) treated with vutrisiran in routine clinical care * Describe treatment patterns of adult patients with ATTR-CM treated with vutrisiran in routine clinical care * Assess health-related quality of life (HRQOL) in adult patients with ATTR-CM treated with vutrisiran in routine clinical care * Assess healthcare resource use (HCRU) in adult patients with ATTR-CM treated with vutrisiran in routine clinical care Compare the long-term effectiveness of vutrisiran versus other approved ATTR-CM treatments in routine clinical care
Sponsor: Alnylam Pharmaceuticals
Yes, this clinical trial (NCT07358078) has an active research site in New Brunswick, NJ that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for transthyretin amyloidosis with cardiomyopathy treatment options in New Brunswick, NJ, this clinical trial (NCT07358078) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New Brunswick research site is actively enrolling participants for this clinical trial. You'll receive care from experienced transthyretin amyloidosis with cardiomyopathy specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all transthyretin amyloidosis with cardiomyopathy clinical trials near you to find additional studies recruiting in your area.
See all cardiomyopathy clinical trials recruiting in New Brunswick — not just this study.
Browse Cardiomyopathy Trials in New Brunswick →